PGNYNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Progyny, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$27.84+0.98 (+3.65%)
Close on Oct 19, 2026
- Market cap
- $2.29B
- P/E (TTM)
- 30.3
- Dividend yield
- –
Progyny, Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fertility benefits services revenue | $850.22M | $833.96M | $830.93M | $809.76M | $786.57M | $766.19M | $729.55M | $713.39M | $709.74M | $688.92M | $676.30M | $648.13M | 64.9% | +8.1% |
| Pharmacy benefits services revenue | $460.54M | $459.17M | $457.73M | $458.93M | $455.40M | $446.99M | $437.67M | $425.34M | $423.25M | $419.36M | $412.30M | $384.85M | 35.1% | +1.1% |
By region
From the segment and revenue-disaggregation notes of Progyny's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.